Pacific Biosciences of California(US:PACB) ZACKS·2025-09-22 23:15Company Performance - Pacific Biosciences of California (PACB) closed at $1.29, with a daily increase of +1.57%, outperforming the S&P 500's gain of 0.44% [1] - The stock has decreased by 7.97% over the past month, underperforming the Medical sector's gain of 1.25% and the S&P 500's gain of 4.03% [1] Earnings Forecast - The upcoming earnings disclosure is expected to show an EPS of -$0.16, reflecting a growth of 5.88% compared to the same quarter last year [2] - Revenue is forecasted to be $40.38 million, indicating a growth of 1.03% year-over-year [2] - For the full year, earnings are projected at -$0.6 per share and revenue at $158.75 million, representing increases of +27.71% and +3.07% respectively from the previous year [3] Analyst Estimates - Recent adjustments to analyst estimates for Pacific Biosciences reflect changing business dynamics, with upward revisions indicating positive sentiment towards the company's operations [4] - The Zacks Rank system, which evaluates these estimate changes, currently ranks Pacific Biosciences at 3 (Hold) [6] Industry Context - The Medical - Instruments industry, which includes Pacific Biosciences, has a Zacks Industry Rank of 92, placing it in the top 38% of over 250 industries [7] - Strong industry rankings correlate with better stock performance, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [7]